Thursday, June 18, 2026

  

Fact check: Can EU countries restrict or ban Israeli settlement imports?

American volunteer prepares to lay down a net ahead of olive picking, next to the settlement West Bank Jewish settlement of Eli, near Nablus. (AP Photo/Dan Balilty)
Copyright AP Photo

By Noa Schumann
Published on

Several EU states are weighing measures against goods from Israeli settlements in the West Bank, East Jerusalem and the Golan Heights – all considered illegal under international law. Some argue that rules that exclude such goods from Israel’s tariff-free trade deal are not being properly enforced.

Calls for tougher measures against goods originating from Israeli settlements are gaining momentum across Europe.

France and Sweden have urged the European Commission to adopt EU-wide restrictions, while countries including Belgium, Spain, Slovenia and Ireland have examined national measures targeting settlement imports.

The debate comes amid the continued expansion of Israeli settlements in the occupied West Bank.

In 2025, Israeli Finance Minister Betzalel Smotrich boasted that 69 new settlements had been approved in recent years, describing it as a record level of expansion.

Data published by the Israeli settlement monitoring group Peace Now indicates that 103 new settlements have been approved in the West Bank since the current Israeli government took office in late 2022.

While the issue is expected to feature prominently at upcoming talks among EU foreign ministers in July, questions are mounting over whether it's legally possible for individual member states to take measures against settlement goods under EU law.

How does the EU currently treat Israeli settlements?

The European Union distinguishes between Israel proper and Israeli settlements in territories occupied since 1967.

Under the EU-Israel Association Agreement, goods originating from these settlements are not eligible for preferential tariff treatment. They may still be imported into the EU, but without the duty-free advantage granted to products originating from within Israel's internationally recognised borders.

The European Commission has also issued guidance requiring products originating from Israeli settlements to be clearly labelled as such.

Since 2004, Israeli exporters have been required to provide postal codes identifying the place of production, enabling the EU to distinguish between goods made in Israel and those produced in settlements.

In 2019, the Court of Justice of the European Union ruled that food products from Israeli settlements must state their origin on labels to avoid misleading consumers.

There is currently no EU-wide ban on imports from Israeli settlements.

Investigations raise questions over enforcement

Several recent investigations have raised questions about whether these rules are being properly implemented.

According to a new investigation by the international NGO Global Echo Litigation Center, products originating from Israeli settlements continue to enter European markets free of tariffs despite existing restrictions.

The organisation analysed more than 30,000 administrative trade records covering exports from Israel to the EU member states between 2017 and 2026.

Based on that analysis, the NGO, which was founded by Israeli and Palestinian lawyers, estimates that around one-fifth of Israeli shipments destined for the EU originated from settlements in the West Bank, East Jerusalem and the Golan Heights.

Palestinian farmers cut onions at a field belong to Jewish settlers, just outside the West Bank Jordan valley Jewish settlement of Tomer. (AP Photo/Oded Balilty)
Palestinian farmers cut onions at a field belong to Jewish settlers, just outside the West Bank Jordan valley Jewish settlement of Tomer. (AP Photo/Oded Balilty) AP Photo

Emily Schaeffer Omer-Man is the founder and executive director of the Global Litigation Center and an expert in international humanitarian law. She told Euronews' fact-checking team, The Cube, that the investigation, based on testimonies from industry representatives, identified three main methods allegedly used to obtain preferential tariff treatment for settlement products.

The first, she said, is what investigators describe as "hiding in plain sight", where paperwork lists Israeli origin and eligibility for preferential treatment, while the actual place of production is redacted. In some cases, the true origin is replaced with an Israeli address that does not correspond to where the goods were produced.

A second method involves mislabelling, with products declared as Israeli-made despite being produced in settlements.

The third consists of mixing settlement goods with products made inside Israel and packaging them together under a single "Product of Israel" label, making their origin difficult to distinguish.

A vineyard in Jewish West Bank settlement of Shilo, near Nablus. (AP Photo/Dan Balilty)
A vineyard in Jewish West Bank settlement of Shilo, near Nablus. (AP Photo/Dan Balilty) AP Photo

A separate investigation by +972 Magazine, an independent online media outlet founded by Palestinian and Israeli journalists, reaches similar conclusions.

In January 2026, it reported that some Israeli settlement wineries exported bottles labelled simply as "Made in Israel", without reference to their origin in the West Bank.

Trade experts say such cases illustrate the challenges authorities face when verifying the origin of imported goods. Agnès Bertrand-Sanz, humanitarian expert and spokesperson for Oxfam Belgium, highlighted the difficulties faced by European customs officials.

"The main responsibility to check the origin of a product lies with the customs authorities, and it really depends on their capacity," she said. "There are so many products arriving in our ports, in the port of Antwerp, in the port of Rotterdam. Of course, it's done on a case-by-case basis, and they don't have time to check everything."

Martin Konečný, director of the Brussels-based think tank the European Middle East Project, said enforcement is further complicated because Israel considers settlements part of its own territory.

Growing calls for stronger measures

Against this backdrop, several European governments argue that the current framework is insufficient.

In a letter co-signed by France and Sweden and sent to the European Commission in April 2026, and seen by The Cube, the two countries call for additional measures targeting products originating from Israeli settlements. Their proposals include tariffs on settlement goods and restrictions on settlement imports through export licensing schemes.

In an interview with Euronews, French deputy trade minister Nicolas Forissier stressed that the letter advocated a pan-European approach.

"With our Swedish friends, we wrote to the Commission and insisted on the necessity to have a common European position on this question, rapidly," he said.

European Union foreign policy chief Kaja Kallas speaks with the media as she arrives for a meeting of EU foreign ministers at the European Council. (AP Photo/Marius)
European Union foreign policy chief Kaja Kallas speaks with the media as she arrives for a meeting of EU foreign ministers at the European Council. (AP Photo/Marius) AP Photo

He added that the EU should not permit imports originating from territories deemed illegally occupied under international law.

"We cannot accept any import of products that are, in fact, produced in illegally occupied territories regarding international law," Forissier said.

Sweden and France argue that settlements are illegal under international law and therefore should not benefit from trade arrangements negotiated with Israel.

Konečný voiced a similar opinion, noting that "the settlements are not a part of Israel."

"They are outside Israel's territory and therefore are not covered by the Association Agreement," he said. “They are also not covered by Israel's membership of the World Trade Organization (WTO) because they are not part of the territory of a WTO member under international law."

Member states push ahead with their own measures

With an EU-wide approach still up in the air, several European governments have taken matters into their own hands.

In late December 2025, Spain implemented a package of trade restrictions against Israel, including a ban on imports of goods originating from Israeli settlements in the West Bank, the Golan Heights and East Jerusalem.

Slovenia has also moved towards prohibiting imports of goods originating from settlements, alongside a separate ban on the export, import and transit of arms and military equipment to and from Israel.

Belgium has announced plans to restrict imports from territories it considers illegally occupied, although no legislation has yet been adopted. Some of the measures put forward so far focus on reducing institutional and economic cooperation rather than imposing a direct trade ban.

Spain's Prime Minister Pedro Sanchez speaks with the media as he arrives for an EU summit at the European Council. (AP Photo/Omar Havana)
Spain's Prime Minister Pedro Sanchez speaks with the media as he arrives for an EU summit at the European Council. (AP Photo/Omar Havana) AP Photo

Ireland is expected to introduce legislation targeting goods originating from Israeli settlements in the West Bank by mid-July 2026.

The Netherlands has meanwhile examined measures aimed at limiting trade in products from the settlements and has indicated it could consider broader restrictions in the future.

Despite these moves by individual member states, any attempt to restrict imports from Israeli settlements could face obstacles. Trade policy is an EU competence, while trade relations with Israel are governed by the EU-Israel Association Agreement, which remains in force.

A European Commission spokesperson told The Cube that trade policy falls under "the EU's exclusive competence" and that "any national measure must be assessed for its compatibility with EU law."

Regarding Spain, the Commission said that Madrid had informed Brussels of its plans but had not yet formally presented the legal text detailing the measures.

A legal debate over the EU-Israel Agreement

Whether member states — or even the EU itself — can legally ban settlement imports remains disputed among legal experts and NGOs.

Konečný argues that the EU-Israel Association Agreement does not include settlement products because settlements fall outside Israel's internationally recognised territory.

Loran Bartels, professor of international law at the University of Cambridge, took a more cautious view.

He said the agreement states that quantitative restrictions on imports and measures having an equivalent effect are prohibited between the EU and Israel.

In his view, this applies not only to products eligible for preferential treatment, but to all goods physically coming from Israel into the EU.

The practical distinction between Israeli and settlement goods remains contentious. As Omer-Man notes, products from both Israel and the settlements in the West Bank and Golan Heights are exported through Israeli ports and handled by Israeli authorities, thus physically departing from Israel proper.

An Israeli soldier stands guard during the inauguration ceremony for the newly legalized Jewish settlement of Yatziv. (AP Photo/Ohad Zwigenberg)
An Israeli soldier stands guard during the inauguration ceremony for the newly legalized Jewish settlement of Yatziv. (AP Photo/Ohad Zwigenberg) AP Photo

Bartels argues that the EU already differentiates settlement products by excluding them from preferential tariffs and requiring specific origin labels.

An import ban, he said, would represent "a qualitatively different measure", as it would go beyond restricting trade preferences and instead prohibit such goods from entering the EU market altogether.

Schaeffer Omer-Man, however, reaches a different conclusion. She argues that the EU's current approach places it in a "compromised situation" that is difficult to reconcile with international law. She also notes that Israel has long opposed any distinction between Israeli and settlement goods, which it sees as "an affront" and contrary to its interests.

The question of whether the EU could take stronger measures also raises the issue of economic leverage.

Michael Lynk, former UN Special Rapporteur on human rights in the Palestinian territories and associate professor of law at Western University in Canada, argues that the EU has more leverage than is often assumed.

"The EU is Israel's largest trading partner," he said, noting that bilateral trade exceeds €43 billion a year and accounts for around a third of Israel’s global trade.

By contrast, trade with Israel represents less than 1% of the EU's external trade. As Lynk puts it: "This trading relationship is far more important to Israel than it is to the EU."




‘Gwynocide’: Gwyneth Paltrow facing backlash for 'tone deaf' luxury Israel real estate advert

‘Gwynocide’: Gwyneth Paltrow faces backlash for 'tone deaf' luxury Israel real estate advert
Copyright AP Photo - Canva

By David Mouriquand
Published on

The Oscar-winning actress has appeared in an advert for luxury penthouses in Israel. The backlash has been intense, with one celebrity asking whether Paltrow is “actually a really, really nasty person” or just “stupid”.

Oscar-winning actress Gwyneth Paltrow has found herself at the heart of an epic backlash, with critics calling her “tone deaf”, “stupid”, and referring to her recent shameless stunt as “Gwynocide”.

The 53-year-old actress turned lifestyle entrepreneur with her brand Goop has appeared in a promotional video for 51 Park, a 51-storey luxury residential development in Herzliya, just north of Tel Aviv.

In the cringeworthy spot, Paltrow narrates a morning routine and praises the appeal of park‑side buildings.

“There’s a reason the world’s most iconic buildings are by a park,” she says.

When asked if the luxury building is in New York. She replies: “Herzliya. Israel.”

This clip has prompted a wave of criticism on social platforms, with commenters citing the ongoing conflict in Gaza and the humanitarian crisis. Indeed, mere miles away from 51 Park, Palestinians are being killed and displaced by settlers and the Israeli military. According to a recent analysis from Oxfam, more Palestinians have been killed in the last three years than in the previous 17 years combined.

While Paltrow, who was raised in an interfaith Jewish-Christian family, did not post the clip herself, many commenters posted Palestinian flags and "Free Palestine" messages on her most recent Instagram posts.

One user on X wrote: "Total moral degradation. While children in Gaza face genocide, starvation, and daily massacres, Gwyneth Paltrow is busy promoting luxury apartments in Israel. No conscience, no ethics just pure complicity with an occupying regime. Absolutely repulsive."

Another posted: "Disgusting woman. Anything for a bit of extra cash I guess."

One X user said: “I used to love Gwyneth Paltrow because of her acting skills. I have not missed a single movie of hers till now. Today I feel like throwing up. For a few bucks, which she already had in abundance, she sold her soul to the devil by promoting a residential development in Israel being developed on a stolen Palestinian land.”

Check out some of the reactions below:

Several public figures also chimed in, calling the advert out for its glaring lack of sensitivity and labelling Paltrow as “complicit”.

Alana Hadid, activist and sister of models Bella and Gigi Hadid, called the campaign "tone deaf" and "complicit”, while influencer Matt Bernstein slammed Paltrow for her participation in the ad, saying: "The level of greed and depravity is truly incomprehensible."

Colin Firth’s ex-wife, Livia Giuggioli, criticised Paltrow for her “disgusting” participation in the advertising campaign and announced she has cancelled Paltrow’s upcoming visit to her farm in Italy.

“I just cancelled Gwyneth Paltrow,” Giuggioli said in a recent Instagram video. “She was supposed to come to the farm in a couple of weeks’ time on a tour, a soil-to-fork farm experience, and we just cancelled her because what she did is completely unacceptable.”

Giuggiolo added: “Making an ad for a luxury condo is as disgusting as it can be for someone [with] privilege. How detached are you from reality? You’re either so detached that you need to be cancelled, because you live in another world. Or you’re actually a really, really nasty person. Or you are stupid. Which are you, Gwyneth Paltrow?”

Paltrow has yet to address the backlash publicly, so the question goes unanswered for now.

Paltrow isn't the only high‑profile celebrity that has faced scrutiny for business investments involving Israeli companies or projects. Last year, we reported that Leonardo DiCaprio faced similar backlash for co-financing a luxury eco-hotel in Israel. DiCaprio had previously been involved in several projects in Israel, including investments in Mobli, a social media startup, and Aleph Farms, a farmed meat company.

Israel has been accused by several human rights organizations of committing genocide in Gaza. Last week, Amnesty International released a 149-page report accusing the Israeli government of carrying out a campaign of “state-sanctioned, state-driven and state-implemented” ethnic cleansing in the occupied West Bank.

Israeli leaders have repeatedly denied the allegations, saying its military campaign was aimed at defeating Hamas.




Lithuania’s plan to send newly trained doctors to rural areas sparks backlash 

Social democrat Orinta Leiputė (third from the left) is one of the initiators of sending newly trained doctors to rural areas.
Copyright Seimas/Gabrielė Ginkutė

By Giedre Peseckyte
Published on

Lithuania — a Baltic country of 2,8 million — plans to tackle medical deserts by sending junior doctors to remote regions. Junior doctors oppose what they see as a “populist” move.

On Thursday, the Lithuanian parliament voted in favour of introducing additional state-funded medical residency positions.

But there is a catch.

The state pays, but the junior doctor, upon admission, signs a contract committing to work for five years in a region that is facing a lack of health care professionals after their residency.

The junior doctors are not impressed and plan to take the case to the Constitutional Court.

“The chosen measure is populist,” Laurynas Maciulevičius, Lithuania’s Junior Doctors Association president, told Euronews Health in a written comment. While the aim is to ensure access to healthcare in regions that face a lack of health professionals, “it does not answer the fundamental question: why do doctors choose, or choose not, to work in regional areas?” Maciulevičius said.

According to social democrat Orinta Leiputė, one of the initiators of the changes, junior doctors will be able to choose to complete residency without committing to work in regions for five years.

“This is a possibility to choose,” Leiputė said in a press release. “If a young doctor does not want studies with obligations, they simply will not choose them and will apply for the places that already exist without an obligation.”

But the chance to get such a place is slim.

Only 20 of 385 state-funded medical residency positions across the country will not require five-year assignments in regions. Leiputė added that the number of state-funded places without obligations remains as it is now. Junior doctors can also choose non-state-funded positions.

Lithuania has more doctors available per 10,000 citizens than the WHO European Region average, placing it ahead of Switzerland and just below Germany. But the general number of doctors is shrinking across European countries amid ageing populations and unattractive working conditions. According to Leiputė, Lithuania will face a shortage of 269 family doctors, 207 internal medicine doctors and 146 paediatricians by 2032. Moreover, eliminating so-called medical deserts in rural areas is a struggle felt across most of the countries.

While junior doctors agree that regions need to ensure access to healthcare, the core of the issue remains unaddressed. “What regions need is not doctors assigned for five years, but a system in which doctors want to stay,” Maciulevičius said, adding that no analysis of the underlying causes, impact assessment, or clear justification has been provided as to why a five-year service obligation model would be the best measure.

Not a silver bullet

Social democrat Leiputė thinks this measure is not a silver bullet, but rather an addition to already existing initiatives aimed at attracting doctors to the regions, such as additional scholarships, relocation grants or housing

“Consideration is also being given to how regional positions can be made more attractive to older physicians who may no longer wish to work in university hospitals or major medical centres, where workloads are particularly demanding,” said Leiputė.

Liberals already condemned the changes, concerned that this will backfire. “‘The parliamentary majority has undermined the constitutional principle of the individual’s freedom of self-determination," the chair of the Liberal Movement said in a press release. “You cannot create forced equality in healthcare; on the contrary, coercion will only push even more doctors to leave and emigrate.”

Several European countries have adopted different strategies to address shortages of healthcare workers in underserved regions, according to the WHO report.

In Finland, authorities have sought to improve access to care by adjusting the geographical distribution of medical training places, expanding the role of nurses, and offering incentives such as higher pay and more flexible working arrangements to encourage doctors to settle in remote areas.

Latvia has taken a different approach. Medical schools give preference to applicants who commit to working in rural areas after completing their training. Doctors practising in underserved regions can also receive monthly bonuses, higher capitation payments and additional financial support, including funding for professional development.

The new rules should take effect from 2027.

 

Drug monopoly extension splits EU ministers in Biotech Act debate

EU health chief, Olivér Várhelyi, said Supplementary Protection Certificates is essential to ensure access to new therapies.
Copyright European Union
By Giedre Peseckyte
Published on

EU health ministers split over a proposal to give certain innovative medicines an extra year of market protection, with EU Health Commissioner arguing the incentive is needed to keep biotech investment in Europe. Incoming Irish presidency, in the meantime, says it will work as quickly as possible.

Cypriots — who hold the rotating presidency of the Council of the European Union until the end of June — tested the waters on what countries aim to achieve through the Commission’s proposed Biotech Act — and, unsurprisingly, an additional year of monopoly rights for certain treatments divided countries.

In the meantime, EU health chief, Várhelyi, said this is the way to have access to new therapies.

The Commission’s proposed additional year of protection — known as Supplementary Protection Certificates — would be granted for treatments that contain a new active substance, have a different mechanism of action from existing treatments, have conducted clinical trials in more than two EU countries and carry out at least one manufacturing step — such as packaging or quality testing — in the EU.

The measure is intended to encourage biotech companies to invest, manufacture and conduct research in Europe.

“We support the idea of incentivising technology in Europe and we support the idea to extend the protection certification system,” Spain’s health minister, Mónica García Gómez, told fellow ministers.

However, not all ministers were as optimistic.

Several countries questioned whether extending exclusivity would ultimately benefit patients, warning that it could delay competition from biosimilars and increase pressure on healthcare budgets.

“We are … reluctant to direct taxpayer money into an industry which refuses to supply small markets or that expects us to pay substantially higher prices than large member states with a higher GDP,” Christopher Farrugia, Valetta’s deputy representative in the EU, said, underlining that the country has “reservations” on the extension of the supplementary protection certificate.

The concern reflects longstanding inequalities in access to medicines across Europe. According to industry data, Malta had access to only 17 innovative medicines approved between 2020 and 2023, compared with 156 in Germany and 142 in Italy.

Estonia voiced similar concerns.

“We want to be very clear about the need for balance,” Estonia said, urging that discussions on the protection periods for innovative medicines must take into account affordability, access to medicines, and the sustainability of health care systems.

Several delegations also questioned whether there is sufficient evidence to justify the measure. The proposal was not accompanied by a dedicated impact assessment, relying instead on analysis carried out for pharmaceutical legislation.

“It is still not clear whether this instrument will be fit to the goals of the industrial and biotech policies of the EU,” Katarzyna Kacperczyk, deputy minister of health, said.

“The Commission's analysis shows that the solution may have significant economic effects and consequences, may affect competition, public spending, and may affect medicinal products availability.”

The health commissioner, Várhelyi, asked about countries’ concerns at the press briefing, said that “if we don't do it, it means most likely these products will never enter Europe, only once the patents have expired.”

As for the costs of such a mechanism, he is “not worried about the funding,” urging countries to focus on prevention to top up their budgets.

“If we push for prevention, it means that we can make significant savings in care; if we do that, it means we will have more funds available for the latest therapies,” Várhelyi told journalists.

Despite disagreements on the extension of protection, ministers were largely aligned on the need to simplify multinational clinical trials, streamline processes, reduce administrative burdens, ensure no overlaps with existing legislation — all this to keep biotech on European soil without compromising patient safety or the quality of products.

Multiple countries — such as Hungary, Czechia, Poland, Estonia, Greece, France, Latvia and Malta — highlighted the need to strengthen support for biosimilars.

“The support measures for biosimilars should, in our view, be reinforced,” Cyril Piquemal, France’s deputy permanent representative at to the EU, said. Kacperczyk, in the meantime, called biosimilars “key for the security and safety of patients in the EU.”

Ireland to shift Biotech Act negotiations into high gear

The incoming Irish Presidency of the Council of the European Union had a message for other countries: negotiations on the Biotech Act need to move fast.

“Because of the external environment, [we] need to move speedily on this particular Act. And ahead of the upcoming Presidency, I'd urge all of you to take your positions as early as possible with that urgency in mind,” Jennifer Carroll MacNeill, Irish health minister, said.

Advancing Europe's biotech environment is “time sensitive for industry, time sensitive for patients,” she said, adding that Europe’s competitors are already gaining ground.

Therefore, she has already appointed the Irish presidency team to work “in an expeditious and streamlined manner with a view to negotiating the Act as quickly as possible.”

The presidency will first focus on the clinical trials, MacNeill said, adding that the incoming presidency wants to “progress measures aimed at strengthening the EU's industrial bio-manufacturing capacity and simplifying procedures to create legislative frameworks that are conducive to innovation.”

 

EU ministers reach consensus on Biotech Act directive

EU countries agreed on their common position on  modified micro-organisms (GMMs) and the processing of organs.
Copyright European Union

By Giedre Peseckyte
Published on

Amid Europe’s push to catch up in the biotechnology field, the EU health ministers agreed how to tweak rules on modified micro-organisms (GMMs) and the processing of organs.

The EU health ministers on 16 June approved a common stance on a piece of legislation that accompanies the Biotech Act regulation — Biotech Act I directive.

The directive tweaks two directives on modified micro-organisms (GMMs) and the processing of organs. The aim — to make them more innovation-friendly, reduce administrative burdens and improve cross-border cooperation in organ transplantation, in a desperate attempt to catch up with biotech frontrunners — such as the US and China.

“Since the adoption of those directives significant progress in biotechnology has taken place,” Neophytos Charalambides, the Cyprus health minister, said. “Updating the respective legislations is therefore not only … a logical consequence, but also an ethical imperative,” he added.

Under the Cypriots’ lead, countries tweaked the Commission’s proposed terminology — for example, replacing the term “low-risk GMMs” with “GMMs eligible for an expedited procedure”, capping indefinitely valid consent to place a GMM on the market at up to ten years, and including provisions specifying that in certain cases processing of personal data can be deemed to be in the public interest.

They also gave themselves more time to comply with updated organ transplantation rules from 24 months to 36 months.

While most countries supported the compromise, the debate revealed a familiar fault line in EU biotechnology policy: how to encourage innovation without weakening safety oversight.

Countries stressed the need to protect personal data, preserve national control over transplantation systems and maintain strong ethical safeguards.

The agreement between the capitals means talks with the European Parliament can start once their negotiating position is reached.

For those discussions, the Cyprus minister suggested taking into account the European Data Protection Supervisor's opinion published at the end of May, which "due to his late arrival, could not be fully taken into account,” he said.

As the Cypriot presidency comes to an end, Ireland will take over responsibility for steering the file through the next stage of negotiations with the Parliament.

In the Parliament, the Health (SANT) and Environment (ENVI) committees are working on the file, with European People's Party’s Adam Jarubas and social democrat Marta Temido leading the work.